Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetologia, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1007/s00125-026-06855-7
- Dergi Adı: Diabetologia
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE, Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Anahtar Kelimeler: Cardiovascular disease, Chronic kidney disease, Consensus report, Glucose-lowering therapy, Holistic care, Lifestyle behaviours, Person-centred care, Social determinants of health, Type 2 diabetes mellitus, Weight management
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet
Özet
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the consensus statement on the management of type 2 diabetes in non-pregnant adults, published since 2006 and last updated In 2022. The target audience is the multidisciplinary healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2022 informed new recommendations. This update has broadened the focus from the management of hyperglycaemia to the holistic management of type 2 diabetes and its risk of associated multiple long-term conditions. Fundamental aspects of diabetes care include promoting healthy lifestyle behaviours (healthy eating, 24 h physical behaviours including sleep, and avoiding tobacco and substance use), alongside the provision of psychological support and weight management interventions. For the management of people living with type 2 diabetes, earlier use, potentially from diagnosis, of sodium–glucose cotransporter 2 (SGLT2) inhibitors or/and glucagon-like peptide-1 (GLP-1)-based therapies to offer organ protection and improve long-term outcomes in type 2 diabetes is advocated. Furthermore, earlier combination use of SGLT2 inhibitors and GLP-1-based therapies should be considered in people with concomitant CVD, chronic kidney disease and heart failure. Finally, the ability to transform outcomes for people living with type 2 diabetes is within our grasp through the consistent, equitable and systematic implementation of strategies and therapies that are already available.